Skip to content
lifestyle.entreprenerd.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
HCW Biologics Inc.
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
June 16, 2026
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
May 27, 2026
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
May 21, 2026
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
May 14, 2026
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
May 14, 2026
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
April 30, 2026
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
April 27, 2026
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
March 17, 2026
←
Previous Page
1
2